Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-44
ISRCTN15088415Phase 2Recruiting
- Sponsor
- Entrada Therapeutics
- Start
- Jul 2025
- Modality
- Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of ENTR-601-44 in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Entrada Therapeutics. Primary endpoint: Safety and tolerability. Started Jul 2025; status: recruiting.
02
Drugs
ENTR-601-44
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on ISRCTN15088415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15088415.